Pulmonary Emphysema Clinical Trial
— BulleEchoOfficial title:
Lung Ultrasound Characterization of Bullous Emphysema
NCT number | NCT04012359 |
Other study ID # | 2019/006/OB |
Secondary ID | |
Status | Completed |
Phase | |
First received | |
Last updated | |
Start date | June 26, 2019 |
Est. completion date | June 26, 2021 |
Verified date | November 2022 |
Source | University Hospital, Rouen |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
Chronic Obstructive Pulmonary Disease (COPD) is a frequent disease affecting a growing number of adults in the world which is responsible for a large public health burden through heavy morbidity and mortality. Emphysema is one of a wide spectrum of pulmonary complications linked to COPD, defined as the abnormal permanent enlargement of the airspaces distal to the terminal bronchioles accompanied by destruction of the alveolar wall. Disease progression is correlated to worsening and enlargement of emphysema lesions, sometimes conflating in sizeable bullae, deleterious to normal mechanical pulmonary function. Bullous emphysema (BE) is sometimes eligible to invasive curative treatment through surgery or interventional bronchoscopy. Diagnosis of BE relies on computerized tomodensitometry (CT), the gold-standard for evaluating pulmonary parenchyma. However, CT is not always available, and bullous emphysema can present as pneumothorax on chest radiography. The practice of lung ultrasound is currently growing in respiratory medicine and emergency departments owing to an increasing amount of evidence showcasing its reliability as a diagnostic tool, most notably for pneumothorax and other pleural diseases. Despite BE having been reported to present similarly to pneumothorax in ultrasound, its characteristics have not yet been precisely described. The primary aim of this study is to describe BE using lung ultrasound. Participants with known BE on CT will undergo a simple ultrasound examination. The secondary aim is to compare the characteristics of BE to those of pneumothorax using lung ultrasound. To achieve this, a second group of participants with currently treated pneumothorax will also undergo lung ultrasound.
Status | Completed |
Enrollment | 35 |
Est. completion date | June 26, 2021 |
Est. primary completion date | June 26, 2021 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - Bullous emphysema group - Consultation or scheduled hospitalization in a Pulmonary Medicine department - Past medical history of emphysema on computerized tomodensitometry dating less than two years - Bullous emphysema with subpleural contact of two or more intercostal spaces on tomodensitometry - Pneumothorax group - Hospitalized in a Pulmonary Medicine department for the treatment of a pneumothorax - Patent pneumothorax visible on chest x-ray dating less than 24 hours Exclusion Criteria: - Bullous emphysema group - Current pneumothorax - Past medical history of pleurodesis or pleural thickening homolateral to the bullous emphysema - All patients - Organ failure (hemodynamic, neurological, respiratory) - Recent thoracic surgery dating less than 7 days with subcutaneous emphysema - Minor participant or otherwise deprived of their freedom or their ability to consent freely - No affiliation to social security |
Country | Name | City | State |
---|---|---|---|
France | Pulmonary Medicine, Thoracic Oncology and Respiratory Intensive Care Department, Rouen University Hospital | Rouen |
Lead Sponsor | Collaborator |
---|---|
University Hospital, Rouen |
France,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Prevalence of various ultrasound signs in the bullous emphysema group, according to a predetermined sonographic evaluation form, following a standardized segmentation of the chest | The following sonographic signs will be investigated :
Pleural sliding (presence/absence) Z lines (presence/absence) A line visibility increase (presence/absence) B line (number per field) pulmonary pulse (presence/absence) lung-point (presence/absence) intercostoaeric line thickness (in mm) For qualitative signs, the investigators will present proportions Quantitative signs will be reported using means, medians and standard-deviations |
2 years | |
Secondary | Prevalence of various ultrasound signs in the pneumothorax group, according to a predetermined sonographic evaluation form, following a standardized segmentation of the chest | The following sonographic signs will be investigated :
Pleural sliding (presence/absence) Z lines (presence/absence) A line visibility increase (presence/absence) B line (number per field) pulmonary pulse (presence/absence) lung-point (presence/absence) intercostoaeric line thickness (in mm) For qualitative signs, the investigators will present proportions Quantitative signs will be reported using means, medians and standard-deviations |
2 years | |
Secondary | Statistical comparison of ultrasound characteristics of bullous emphysema and pneumothorax | Calculation of sensitivity values of lung ultrasound for bullous emphysema for each sonographic sign. Study design prohibits calculation of specificity.
A quantitative discrete score will be constructed by enumerating signs which are positive in favor of bullous emphysema, able to discriminate between both diseases. AUC will be calculated. An AUC < 0.75 will be considered as insufficient for establishing lung ultrasound as a diagnostic test for bullous emphysema. An AUC > 0.75 would prompt further studies. |
2 years |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT00995852 -
Unilateral Versus Bilateral Endoscopic Lung Volume Reduction A Comparative Case Study
|
Phase 2/Phase 3 | |
Completed |
NCT01860898 -
A Phase I Study of iPS Cell Generation From Patients With COPD
|
N/A | |
Completed |
NCT00123422 -
Innovation in Pulmonary Rehabilitation
|
N/A | |
Recruiting |
NCT02879331 -
Clinical Study to Evaluate the Exercise Capacity in Patients With Severe Emphysema Treated With Coils
|
N/A | |
Completed |
NCT01507415 -
Do the SPPB and 4-metre Gait Speed Predict Hospital Readmission in Patients Hospitalised for Acute Exacerbation if COPD?
|
N/A | |
Completed |
NCT01051258 -
AeriSeal System for Lung Volume Reduction
|
Phase 1/Phase 2 | |
Completed |
NCT00680056 -
Add-on Effects of Tiotropium Over Formoterol in Exercise Tolerance on Chronic Obstructive Pulmonary Disease Patients
|
Phase 4 | |
Completed |
NCT01872624 -
Safety Study of Bone-marrow Derived Mesenchymal Stromal Cells Associated With Endobronchial Valves in Emphysema
|
N/A | |
Completed |
NCT01110252 -
Safety Study of Cell Therapy to Treat Chronic Obstructive Pulmonary Disease
|
N/A | |
Completed |
NCT00517998 -
Israeli Biologic Lung Volume Reduction (BLVR) Phase 1 Emphysema Study
|
Phase 1 | |
Terminated |
NCT00205920 -
Netherlands 10 mL Bronchoscopic Lung Volume Reduction (BLVR) Phase 1/2 Emphysema Study - Initial Formulation
|
Phase 2 | |
Withdrawn |
NCT01849159 -
Clinical Study of the Efficacy and Safety of the Application of Allogeneic Mesenchymal (Stromal) Cells of Bone Marrow, Cultured Under the Hypoxia in the Treatment of Patients With Severe Pulmonary Emphysema
|
Phase 1/Phase 2 | |
Completed |
NCT01869205 -
The Effect and Mechanism of Bronchoscopic Lung Volume Reduction by Endobronchial Valve in Korean Emphysema Patients
|
Phase 3 | |
Terminated |
NCT01320566 -
A Continuation Study of the AeriSeal® System Administered at 3 to 4 Sites During a Single Treatment Session for Lung Volume Reduction in Patients With Advanced Emphysema
|
Phase 2/Phase 3 | |
Completed |
NCT00683722 -
PROCHYMAL™ (Human Adult Stem Cells) for the Treatment of Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)
|
Phase 2 | |
Active, not recruiting |
NCT04465461 -
Video Assisted Thoracic Surgery (VATS) Fissure Completion Prior to Zephyr® Endobronchial Valve Insertion
|
N/A | |
Recruiting |
NCT04918706 -
Allogeneic MSC Treatment for Pulmonary Emphysema
|
Phase 2 | |
Terminated |
NCT01449292 -
Study of the AeriSeal System for HyPerInflation Reduction in Emphysema (ASPIRE)
|
Phase 3 | |
Completed |
NCT00347659 -
US 10 mL Biologic Lung Volume Reduction (BLVR) Phase 1 Emphysema Study
|
Phase 1 | |
Recruiting |
NCT02827721 -
Evaluation of Novel Lung Function Parameters in Patients With Chronic Obstructive Pulmonary Disease (COPD)
|